Vectura Group plc

Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura’s main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25 billion.


Vectura seeks to develop certain programmes itself where this will optimise value. Vectura’s formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura’s business strategy.

For further information, please visit Vectura’s website at www.vectura.com

Type: NORMAL
Address: One Prospect West, Chippenham, Wiltshire, SN14 6FH
Website: www.vectura.com
Phone: +44 (0)1249 667700
 
This website requires Flash Player 9 or later. If you can not view this site you probably need to update your system with this plug-in for your browser.